未登录

G

Giuliana Cavalloni

University of Turin

H指数:21

被引数:2,089

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Fluoropyrimidine-induced cardiotoxicity in colorectal cancer patients: a prospective observational trial (CHECKPOINT)

ONCOLOGY REPORTS

IF3.9

2022-12-216

OAAI

Paclitaxel Restores Sensitivity to Chemotherapy in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma

紫杉醇在多药耐药肝内胆管癌的临床前模型中恢复对化疗的敏感性

FRONTIERS IN ONCOLOGY

IF3.3

2022-02-175

OAAI

The protease-inhibitor SerpinB3 as a critical modulator of the stem-like subset in human cholangiocarcinoma

LIVER INTERNATIONAL

IF5.2

2021-09-1618

OAAI

Correnti, Margherita; Cappon, Andrea; Pastore, Mirella; Piombanti, Benedetta; Lori, Giulia; Oliveira, Douglas V. P. N.; Munoz-Garrido, Patricia; Lewinska, Monika; Andersen, Jesper B.; Coulouarn, Cedric; Sulpice, Laurent; Neia, Caterina Peraldo; Cavalloni, Giuliana; Quarta, Santina; Biasiolo, Alessandra; Fassan, Matteo; Ramazzotti, Matteo; Parri, Matteo; Recalcati, Stefania; Tommaso, Luca; Campani, Claudia; Invernizzi, Pietro; Torzilli, Guido; Marra, Fabio; Pontisso, Patrizia; Raggi, Chiara

Proteomic analysis identifies deregulated metabolic and oxidative-associated proteins in Italian intrahepatic cholangiocarcinoma patients

IF3.4

2021-07-287

OAAI

The protease-inhibitor serpinB3 as a critical modulator of the stem-like subset in human cholangiocarcinoma

DIGESTIVE AND LIVER DISEASE

IF3.8

2021-03-010

OAAI

Predictive factor of cardiotoxicity in fluoropyrimidine-treated colorectal cancer patients: Interim analysis of the prospective observational CHECKPOINT trial

ANNALS OF ONCOLOGY

IF65.4

2020-09-011

OAAI

Characterization of cholangiocarcinoma primary, circulating and metastatic stem-like cells

JOURNAL OF HEPATOLOGY

IF33

2019-04-010

PREAI

Cholangiocarcinoma primary, circulating and metastatic stem-like cells

DIGESTIVE AND LIVER DISEASE

IF3.8

2019-02-010

PREAI

Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma

IF3.7

2018-06-0514

OAAI

The protease-inhibitor SerpinB3 outlines a stem-like subset in human cholangiocarcinoma

DIGESTIVE AND LIVER DISEASE

IF3.8

2018-02-010

PREAI

Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation

KRAS突变肝内胆管癌移植瘤模型的建立

IF3.4

2016-02-1138

OAAI

Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models

IF3.4

2014-12-058

OAAI

Antitumor activity, gene and miRNA modulation upon ET-743 treatment in an intrahepatic cholangiocarcinoma patient-derived xenograft model

CANCER RESEARCH

IF16.6

2014-10-010

PRE

Screening for the FIG-ROS1 Fusion in Biliary Tract Carcinomas by Nested PCR

GENES CHROMOSOMES & CANCER

IF2.8

2014-09-1824

PREAI

Biliary tract carcinomas: From chemotherapy to targeted therapy

胆道癌: 从化疗到靶向治疗

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

IF5.6

2013-02-0135

PRE

Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas

MOLECULAR CANCER THERAPEUTICS

IF5.5

2012-07-0515

OAAI

Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer

IF3.4

2011-01-2596

OAAI

HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib

BREAST CANCER RESEARCH AND TREATMENT

IF3

2010-12-0945

PREAI

Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas

IF3.4

2010-11-18168

OAAI

Sorafenib blocks tumor growth, angiogenesis, and metastatic potential in preclinical models of osteosarcoma through the inhibition of ERK1/21 MCL-1, and ezrin pathways

MOLECULAR CANCER THERAPEUTICS

IF5.5

2009-12-010

PRE